论文部分内容阅读
评价聚乙二醇干扰素α-2a(PegaIFNα-2a)治疗慢性乙型肝炎(CHB)的远期疗效。72例CHB患者按1∶1.4比例随机分配到治疗组和对照组。治疗组(30例)予PegaIFNα-2a 180μg皮下注射,每周1次,疗程48周。对照组(42例)予普通干扰素500万单位,皮下注射,隔日1次,疗程48周。治疗结束后随访72周。结果在随访72周时,治疗组的HBeAg定量、HBeAg的转阴率、HBeAg/抗-HBe血清转换率、HBVDNA定量的对数值、HBVDNA转阴率、ALT的复常率及完全应答率均显著优于对照组,而且保持持久的应答效果。治疗组有3例HBsAg转阴,并且持续到治疗结束后72周,对照组无1例转阴。研究提示PegaIFNα-2a治疗慢性乙型肝炎能有效地抑制其病毒复制,且保持持久性应答。
To evaluate the long-term efficacy of PegaIFNα-2a in the treatment of chronic hepatitis B (CHB). 72 CHB patients were randomly assigned to the treatment group and the control group according to the ratio of 1: 1.4. The treatment group (30 cases) to PegaIFNα-2a 180μg subcutaneously once a week for 48 weeks. The control group (n = 42) received 5 million units of common interferon subcutaneously once a day for 48 weeks. After treatment for 72 weeks. Results At the 72-week follow-up, HBeAg quantification, HBeAg negative rate, HBeAg / anti-HBe seroconversion rate, HBVDNA quantitative logarithm, HBVDNA negative rate, normal ALT rate and complete response rate Better than the control group, but also to maintain a lasting response. In the treatment group, 3 cases of HBsAg were negative, and continued until 72 weeks after the end of treatment, no one in the control group turned negative. Studies suggest PegaIFNα-2a treatment of chronic hepatitis B can effectively inhibit its viral replication, and maintain a lasting response.